1[1]Kahn SE. Regulation of beta- cell function in vivo: from health to disease DiabetesRev,1996, 4 (4) 372-389
2[2]Polonsky KS, Sturis J, Bell GI. Non- insulin - dependent diabetes mellitus - a genetically programmed failure of the beta cell to cornpensate for insulin resistance. N Engl J Med,1996, 334 (12): 777-783
3[3]Perfetti R, Mathur R, Egan JM. New insulin secretagogues for the treatnent of type 2diabetes. Dis Manage Clin Outcomes, 1998,Jul-Aug (1): 129- 135
4[4]Calls- Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes, 1987, 36:1167- 1172
5[5]Luzi L, DeFronzo RA. Effect of loss of first -phase insulin secretion on hepatic glucose disposal in humans. Am J Physiol, 1989,257, 241 - 246
6[6]Bruce DG, Chisholm GI, Storlien LH, et al. Physiological importance of deficiency in early prandial insulin secretion in non- insulin -dependent diabetes. Diabetes, 1988, 37:736 - 744
7[7]Bruttomesso D, Pianta A, Maii A, et al.Restoration of early rise in plasma insulin levels improves the glucose tolerance in type 2 diabetic patients. Diabetes, 1999, 48: 99-105
8[8]Fuitani S, Yada T A novel D- phenylalanine - derivative hypoglycemic agent A - 4116 increases cytosolic free Ca2+ in rat pancreatic β- cells by stimulating Ca2+ influx. Endocrinology, 1994, 3 (134): 1395-1400
9[9]Hu S, Wang S, Dunning BE. Tissue selectively of nateglinide: study on cardiovascular and β - cell KATP channels [ abstract ] Diabetes, 1999, 48 (1): 249
10[10]Horton E, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metfirmin improves glycemic control by reducing mealtime glucose spikes in type 2diabetes [ abstract ]. Diabetes, 2000, 49(1): 112
